Shots:

• Avidity to receive $20M upfront- $15M equity investment- $405M as development- regulatory & commercial milestones for each target and royalties on sales. Lilly to get WW rights to develop and commercialize the products to be developed in immunology and other indications
• The companies will develop & commercialize RNA-based therapies with the combination of tissue selectivity of mAb with oligonucleotide-based candidates utilizing Avidity's AOC technology
• Avidity’s antibody oligonucleotide conjugate (AOC) technology combines the cellular and tissue selectivity of mAbs with oligonucleotide-based therapies- modulating RNA in diverse cell types and tissues including muscle- heart- liver- tumors and immune cells

Ref: Eli Lilly | Image: Chemical Industry Digest